Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (9669)	11/15/2003 4:58:08 PM
From: Icebrg	Read Replies (1) \| Respond to of 9719

The merger was completed last Wednesday. Shareholders in BGEN will receive 1.15 shares in BIIP for each share in BGEN, while shareholders in IDPH will keep their shares, as it was IDPH who made an offer for BGEN. So in your model you should - if I have understood this correctly - just change IDPH into BIIP and everything should be OK. Talking about being OK. There are some doubts with regard to the potential of the new company. One analyst who tried to accentuate the positive was however Soundview Technology Group's analyst Ronald Renaud who on Wednesday initiated coverage of Biogen Idec with a rating of "outperform." The motivation: "Although Biogen brings a slower near-term growth rate and Idec brings an anemic pipeline, we believe the merged company can streamline expenses and focus on current and future growth opportunities," he said in a report. Erik